DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishigami, M.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishigami, M.
Right arrow Articles by Sugiyama, Y.

Vol. 29, Issue 3, 282-288, March 2001

A Comparison of the Effects of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors on the CYP3A4-Dependent Oxidation of Mexazolam in Vitro

Michi Ishigami, Tomoyo Honda, Wataru Takasaki, Toshihiko Ikeda, Toru Komai, Kiyomi Ito, and Yuichi Sugiyama

Drug Metabolism and Pharmacokinetics Research Laboratories and Product Strategy Department, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (M.I., T.H., W.T., T.I., T.K.); School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo, Japan (K.I.); and Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.S.)

HMG-CoA reductase inhibitors can be divided into two groups: those administered as the prodrug, i.e., the lactone form (e.g., simvastatin and lovastatin), and those administered in the active form, i.e., the acid form (e.g., pravastatin, fluvastatin, atorvastatin, and cerivastatin). In this study, the influence of the lactone and acid forms of various HMG-CoA reductase inhibitors on metabolism by CYP3A4, a major cytochrome P450 isoform in human liver, was investigated by determining the in vitro inhibition constant (Ki value) using an antianxiety agent, mexazolam, as a probe substrate. In human liver microsomes, all the lactone forms tested inhibited the oxidative metabolism of mexazolam more strongly than did the acid forms, which have lower partition coefficient (logD7.0) values. In addition, the degree of inhibition of mexazolam metabolism tended to increase with an increasing logD7.0 value of the HMG-CoA reductase inhibitors among the lactone and acid forms. In particular, pravastatin (acid form), which has the lowest logD7.0 value, failed to inhibit CYP3A4 activity. Taking account of the lipophilicity of the inhibitors, in conjunction with the CYP3A4-inhibitory activity, could be very useful in predicting drug interactions between substrates of CYP3A4 and HMG-CoA reductase inhibitors.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
M. Kokudai, N. Inui, K. Takeuchi, T. Sakaeda, Y. Kagawa, and H. Watanabe
Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers
J. Clin. Pharmacol., May 1, 2009; 49(5): 568 - 573.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. S. Madsen, E. Janovitz, R. Zhang, Van Nguyen-Tran, C. S. Ryan, X. Yin, H. Monshizadegan, M. Chang, C. D'Arienzo, S. Scheer, et al.
The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Chen, J. Lin, T. Smolarek, and L. Tremaine
P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice
Drug Metab. Dispos., October 1, 2007; 35(10): 1725 - 1729.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Laudi, S. Trump, V. Schmitz, J. West, I. F. McMurtry, H. Mutlak, U. Christians, J. Weimann, U. Kaisers, and W. Steudel
Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin
Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L630 - L638.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama
Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 876 - 882.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Chen, R. J. Mireles, S. D. Campbell, J. Lin, J. B. Mills, J. J. Xu, and T. A. Smolarek
DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1
Drug Metab. Dispos., April 1, 2005; 33(4): 537 - 546.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. N. Johnson-Anuna, G. P. Eckert, J. H. Keller, U. Igbavboa, C. Franke, T. Fechner, M. Schubert-Zsilavecz, M. Karas, W. E. Muller, and W. G. Wood
Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 786 - 793.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Kikuchi, H. Kusuhara, T. Abe, H. Endou, and Y. Sugiyama
Involvement of Multiple Transporters in the Efflux of 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors across the Blood-Brain Barrier
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1147 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. R. Mehra, P. A. Uber, K. Vivekananthan, S. Solis, R. L. Scott, M. H. Park, R. V. Milani, and C. J. Lavie
Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival
J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1609 - 1614.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Ishigami, W. Takasaki, T. Ikeda, T. Komai, K. Ito, and Y. Sugiyama
Sex Difference in Inhibition of In Vitro Mexazolam Metabolism by Various 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in Rat Liver Microsomes
Drug Metab. Dispos., August 1, 2002; 30(8): 904 - 910.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. M. Fowler, J. M. Taylor, T. Friedberg, C. R. Wolf, and R. J. Riley
CYP3A4 Active Site Volume Modification by Mutagenesis of Leucine 211
Drug Metab. Dispos., April 1, 2002; 30(4): 452 - 456.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.